000661 Changchun High-Tech Industries
- 100.66
- +0.07+0.07%
Changchun High-Tech Industries News
Are Robust Financials Driving The Recent Rally In Changchun High-Tech Industry (Group) Co., Ltd.'s (SZSE:000661) Stock?
Changchun High-Tech Industries (000661.SZ): The clinical trial application for the type II simple herpes virus mRNA vaccine of the controlled subsidiary has been approved.
Gelonghui reported on December 20 that Changchun High-Tech Industries (000661.SZ) announced that its holding subsidiary - Changchun Baike Biotechnology Co., Ltd. (hereinafter referred to as "Baike Biotechnology") has received the approval notice for drug clinical trials issued by the National Medical Products Administration. The clinical trial application for the Type II herpes simplex virus mRNA vaccine has been approved. Type II herpes simplex virus infection, which leads to genital herpes, is a contagious disease primarily spread through sexual contact, characterized by easy transmission, recurrence, and a lack of effective cure, becoming a serious public health issue. To prevent the occurrence of genital herpes, already several...
Changchun High-Tech Industry's Unit Gets Registration Certificate for Luteinizing Hormone Kit
Changchun High-Tech Industries (000661.SZ): The luteinizing hormone detection kit has obtained the medical instruments registration certificate.
Gelonghui, December 18th丨Changchun High-Tech Industries (000661.SZ) announced that its subsidiary Shanghai SaiZeng Medical Technology Co., Ltd. received the "Medical Instrument Registration Certificate" (in vitro diagnostic reagents) issued by the Shanghai Municipal Drug Administration. Product name: Luteinizing Hormone Test Kit (fluorescent immunochromatography method). The acquisition of this medical instrument registration certificate further enriches the company's product line and will have a positive impact on the company's business development.
Changchun High-Tech Industry's Unit Gets Nod to Trial Advance Solid Tumors Treatment Tablets
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
A Piece Of The Puzzle Missing From Changchun High-Tech Industry (Group) Co., Ltd.'s (SZSE:000661) Share Price
Changchun High-Tech Industry Issues 450 Million Yuan Convertible Bonds to Shareholder
changchun high-tech industries (000661.SZ): has repurchased 0.34% of the shares accumulated.
Gelonghui, December 2nd丨Changchun High-Tech Industries (000661.SZ) announced that as of November 30, 2024, the company has cumulatively repurchased 1,359,100 shares of its own stock through a dedicated repurchase securities account via centralized bidding trade, accounting for 0.34% of the company's total share capital. The highest fill price was 112.25 yuan/share, the lowest fill price was 106.62 yuan/share, and the total transaction amount was 149,993,961.30 yuan (including transaction fees). The implementation of the company's share repurchase complies with relevant laws and regulations and the company's established share repurchase plan.
Changchun high-tech industries (000661.SZ): Progesterone injection (II) included in the national medical insurance directory.
According to the notice issued by the National Medical Insurance Administration and the Ministry of Human Resources and Social Security on the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Pharmaceutical Catalogue (2024)" (Medical Insurance Development [2024] No. 33), Changchun High-tech Industries (000661.SZ) announced that Jinsaixin Progesterone Injection (Ⅱ) (1.112ml:25mg) of Changchun Jinsai Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Changchun High-tech Industries (Group) Co., Ltd., has been included in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Pharmaceutical Catalogue (2024)". This time, Jinsaixin Huang
Estimating The Fair Value Of Changchun High-Tech Industry (Group) Co., Ltd. (SZSE:000661)
Gelonghui Announcement Highlights | Guangxi Guiguan Electric Power: plans to invest 0.396 billion yuan to build the Duyang Wind Power Phase II project; Changchun High-Tech Industries: plans to spend 0.3 billion yuan to -0.5 billion yuan for share buybacks
【Performance Data】 china state construction engineering corporation (601668.SH): From January to October, the total amount of newly signed contracts reached 3572.5 billion yuan, a year-on-year increase of 4.4%. hainan airlines holding (600221.SH): In October, passenger transport capacity increased by 17.05% year-on-year. hainan airport infrastructure (600515.SH): In October, passenger throughput was 1.8491 million, a year-on-year decrease of 4.03%. juneyao airlines (603885.SH): In October, passenger turnover increased by 19.26% year-on-year. china shenhua energy (601088.SH): In October, coal sales reached 38.2 million tons, a year-on-year increase of 1.9%.
Changchun high-tech industries (000661.SZ): plans to spend 0.3 billion to -0.5 billion yuan to repurchase shares.
On November 15, Gelonghui reported that changchun high-tech industries (000661.SZ) announced the company plans to use its own funds and funds from financial institutions for a share buyback through centralized bidding, to repurchase a portion of the company's publicly issued ordinary shares (A-shares) in RMB, which will all be used for the subsequent implementation of the stock-based incentive or employee stock ownership plan for the core team of the company and its subsidiaries. The total amount planned for the share buyback will not be less than RMB 0.3 billion (inclusive) and not more than RMB 0.5 billion (inclusive), with a repurchase price not exceeding RMB 160.00 per share. Based on the upper limit of the total amount planned for the buyback of RMB 0.5 billion, it is expected that the repurchase will...
Changchun High-Tech Industry Gets China Marketing Nod for Growth Hormone Injection
Securing the indication of the world's first long-acting growth hormone ISS globally, is there a solution to the situation of both revenue and net profit decline at Changchun High-tech Industries? | Announcement for quick reading
①On the 5th, changchun high-tech industries announced that its long-acting growth hormone has been approved for ISS indication. In August of this year, this variety was also approved for the growth disorder in girls with gonadal dysgenesis (Turner syndrome); ②In the first three quarters of this year, changchun high-tech industries' performance and profitability both declined. Whether the main products that have been on the market for 10 years can have new sales volume is widely watched.
Changchun High-Tech Industry (Group) Co., Ltd. Just Missed Revenue By 19%: Here's What Analysts Think Will Happen Next
Changchun Hi-Tech: Report for the third quarter of 2024
Changchun high-tech industries (000661.SZ) intends to invest 0.35 billion yuan to establish a partnership enterprise and make investment layout around the company's upstream and downstream industry chain.
Changchun High-Tech Industries (000661.SZ) issued an announcement to further enhance industrial investment capabilities and improve capital utilization efficiency...
Changchun High-Tech Industries (000661.SZ) released its performance for the first three quarters, with a net income of 2.789 billion yuan, a decrease of 22.80% year-on-year.
Changchun High-Tech Industries (000661.SZ) released the third quarter report of 2024. In the first three quarters, the company achieved revenue...
changchun high-tech industries (000661.SZ): net income of 2.789 billion yuan in the first three quarters, a year-on-year decrease of 22.80%.
Guolonghui, October 25th - Changchun High-tech Industries (000661.SZ) announced its third quarter report for 2024, achieving revenue of 10.388 billion yuan in the first three quarters, a decrease of 2.75% year-on-year; net income attributable to shareholders of the listed company was 2.789 billion yuan, down 22.80% year-on-year; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 2.841 billion yuan, a decrease of 21.45% year-on-year; basic earnings per share was 6.93 yuan.
No Data
